{"id":"c89b263685637bcfa13d13fc7fcec2fa9ea467ba742faff28cf118368f98591c","title":"MIT Technology Review reports on Insilico’s AI-designed drug candidate","argument":"MIT Technology Review’s article, published March 20, 2024, examines Insilico Medicine’s candidate drug for idiopathic pulmonary fibrosis and the claim that AI helped select both its biological target and chemical structure. Alex Zhavoronkov, Insilico’s co-CEO, says the candidate’s progress through animal testing in 18 months demonstrates that AI can speed drug discovery. The article also describes the candidate’s progress to Phase II trials, which seek initial evidence of whether it helps patients; it does not report that the drug works.\n\nThe article places that claim against a broader uncertainty: many AI-designed drug candidates are advancing, but the cited BCG analysis could not determine whether they progress faster than conventional drugs, and no AI drugs had completed the journey to approval. It also notes that important failures can occur in later patient tests. Zhavoronkov says the drug may still fail and compares its later development to moving at “the speed of traffic.” The article’s central stake is whether the candidate can help people with a fatal lung disease—not whether AI alone can make that happen. Whether this drug helps patients remains unknown.","topicIds":["investment-booms-and-busts"],"domain":"other","claimType":"attributed reading","limits":"Text as retrieved on October 28, 2026; originally published March 20, 2024.","speaker":{"name":"MIT Technology Review","roleAtSource":"Publisher"},"source":{"title":"An AI-driven “factory of drugs” claims to have hit a big milestone","publisher":"MIT Technology Review","format":"Article","url":"https://www.technologyreview.com/2024/03/20/1089939/a-wave-of-drugs-dreamed-up-by-ai-is-on-its-way/","publishedAt":"2024-03-20T10:30:00Z","dateBasis":"Date from the publisher’s own records, through its API."},"evidence":[{"text":"Zhavoronkov says AI helped Insilico choose both the drug’s target and chemical structure.","excerpt":"AI software not only helped decide what target inside a cell to interact with, but also what the drug’s chemical structure should be.","url":"https://www.technologyreview.com/2024/03/20/1089939/a-wave-of-drugs-dreamed-up-by-ai-is-on-its-way/","relationship":"Source-stated"},{"text":"Zhavoronkov says the candidate’s rapid progress through animal testing demonstrates that AI can make drug discovery faster.","excerpt":"it took 18 months for the compound to be synthesized and complete testing in animals—is a demonstration that AI can make drug discovery faster.","url":"https://www.technologyreview.com/2024/03/20/1089939/a-wave-of-drugs-dreamed-up-by-ai-is-on-its-way/","relationship":"Source-stated"},{"text":"The article says the candidate advanced to Phase II trials, which will seek initial evidence of whether it helps patients.","excerpt":"The drug has since advanced to Phase II trials in China and the U.S., which will seek initial evidence of whether it’s actually helpful to patients","url":"https://www.technologyreview.com/2024/03/20/1089939/a-wave-of-drugs-dreamed-up-by-ai-is-on-its-way/","relationship":"Source-stated"},{"text":"The article says the cited BCG analysis could not determine whether AI-enabled drugs were progressing faster than the conventional pace, and that no AI drugs had completed the journey to approval.","excerpt":"What BCG couldn’t determine was if AI-enabled drugs were progressing more quickly than the conventional pace","url":"https://www.technologyreview.com/2024/03/20/1089939/a-wave-of-drugs-dreamed-up-by-ai-is-on-its-way/","relationship":"Source-stated"},{"text":"Zhavoronkov says the candidate can still fail and that later development will move at the speed of traffic.","excerpt":"“It’s like a Tesla. The initial 0 to 60 is very fast, but after that you are moving at the speed of traffic,” he says. “And you can still fail.”","url":"https://www.technologyreview.com/2024/03/20/1089939/a-wave-of-drugs-dreamed-up-by-ai-is-on-its-way/","relationship":"Source-stated"}],"sourceMedia":{"status":"unchecked","sourceUrl":"https://www.technologyreview.com/2024/03/20/1089939/a-wave-of-drugs-dreamed-up-by-ai-is-on-its-way/","checkedAt":null,"items":[]},"assumptions":[],"openQuestion":{"attribution":"Open question","text":"What evidence will the Phase II trials provide about whether Insilico’s candidate helps patients with idiopathic pulmonary fibrosis?"},"whatWouldChangeView":{"attribution":"Change condition not recorded","text":""},"editorialComparisons":[],"live":{"title":"MIT Technology Review reports on Insilico’s AI-designed drug candidate","summary":"MIT Technology Review’s article, published March 20, 2024, examines Insilico Medicine’s candidate drug for idiopathic pulmonary fibrosis and the claim that AI helped select both its biological target and chemical structure. Alex Zhavoronkov, Insilico’s co-CEO, says the candidate’s progress through animal testing in 18 months demonstrates that AI can speed drug discovery. The article also describes the candidate’s progress to Phase II trials, which seek initial evidence of whether it helps patients; it does not report that the drug works.\n\nThe article places that claim against a broader uncertainty: many AI-designed drug candidates are advancing, but the cited BCG analysis could not determine whether they progress faster than conventional drugs, and no AI drugs had completed the journey to approval. It also notes that important failures can occur in later patient tests. Zhavoronkov says the drug may still fail and compares its later development to moving at “the speed of traffic.” The article’s central stake is whether the candidate can help people with a fatal lung disease—not whether AI alone can make that happen. Whether this drug helps patients remains unknown.","question":"What evidence will the Phase II trials provide about whether Insilico’s candidate helps patients with idiopathic pulmonary fibrosis?","claims":[{"text":"Zhavoronkov says AI helped Insilico choose both the drug’s target and chemical structure.","excerpt":"AI software not only helped decide what target inside a cell to interact with, but also what the drug’s chemical structure should be.","support":"source-stated"},{"text":"Zhavoronkov says the candidate’s rapid progress through animal testing demonstrates that AI can make drug discovery faster.","excerpt":"it took 18 months for the compound to be synthesized and complete testing in animals—is a demonstration that AI can make drug discovery faster.","support":"source-stated"},{"text":"The article says the candidate advanced to Phase II trials, which will seek initial evidence of whether it helps patients.","excerpt":"The drug has since advanced to Phase II trials in China and the U.S., which will seek initial evidence of whether it’s actually helpful to patients","support":"source-stated"},{"text":"The article says the cited BCG analysis could not determine whether AI-enabled drugs were progressing faster than the conventional pace, and that no AI drugs had completed the journey to approval.","excerpt":"What BCG couldn’t determine was if AI-enabled drugs were progressing more quickly than the conventional pace","support":"source-stated"},{"text":"Zhavoronkov says the candidate can still fail and that later development will move at the speed of traffic.","excerpt":"“It’s like a Tesla. The initial 0 to 60 is very fast, but after that you are moving at the speed of traffic,” he says. “And you can still fail.”","support":"source-stated"}],"limitations":["Text as retrieved on October 28, 2026; originally published March 20, 2024."],"mediaId":null,"correctionReason":null,"id":"c89b263685637bcfa13d13fc7fcec2fa9ea467ba742faff28cf118368f98591c","publicationId":"42fc52ab-29af-fbcf-fc11-3a77d7c14ecc","version":1,"sourceUrl":"https://www.technologyreview.com/2024/03/20/1089939/a-wave-of-drugs-dreamed-up-by-ai-is-on-its-way/","sourceTitle":"An AI-driven “factory of drugs” claims to have hit a big milestone","publisher":"MIT Technology Review","publishedAt":"2024-03-20T10:30:00Z","originalPublished":{"value":"2024-03-20T10:30:00Z","precision":"instant","basis":"backfill:api_published"},"firstObservedAt":"2026-10-28T15:02:06.919Z","createdAt":"2026-11-20T20:23:09.539Z","historical":true,"entityIds":[],"topicIds":["investment-booms-and-busts"],"media":[],"sourceMedia":{"status":"unchecked","sourceUrl":"https://www.technologyreview.com/2024/03/20/1089939/a-wave-of-drugs-dreamed-up-by-ai-is-on-its-way/","checkedAt":null,"items":[]},"editorialDecision":{"outcome":"accept","mediaId":null,"inputHash":"4c7c7daa022808c3915e1f92727037ed8da5ab10bfbe619a9c992a6aa0fac3c1","rubricVersion":"unrecorded","provider":"typesafe","model":"jev-1.13.0","reasonCodes":["bridge_admitted_by_model"],"confidence":0.73,"decidedAt":"2026-10-28T15:02:04.896Z"},"provenance":{"textHash":"d3fee5c2bda2b8df2b91fbe2abaf5e7e65eeb499231265b768f051d2a3006888","observationId":"23c1c4bc09635a1f34db6362f412fc87a7639ebe0cb56fe00b70e2573637ddc7","retrievedAt":"2026-10-28T15:03:52.567Z","kind":"publisher-page","preparer":{"model":"openai/gpt-6-luna","runId":"15435351-02b8-3cfc-96ca-45f88c173c3e"},"reviewer":{"model":"anthropic/claude-opus-5.5","runId":"e1e21f2a-c6d3-d063-7ef1-c4a9b61207eb"}},"audit":{"status":"uncertain","reviewedAt":"2026-11-20T20:18:41.313Z","model":"anthropic/claude-opus-5.5"}},"canonicalUrl":"https://escapemeridian.com/readings/mit-technology-review-reports-on-insilico-s-ai-designed-drug-c89b2636","formats":{"html":"/readings/mit-technology-review-reports-on-insilico-s-ai-designed-drug-c89b2636","markdown":"/readings/mit-technology-review-reports-on-insilico-s-ai-designed-drug-c89b2636.md","json":"/readings/mit-technology-review-reports-on-insilico-s-ai-designed-drug-c89b2636.json"},"attribution":"Headline and summary by Escape Meridian, prepared by Luna from the attributed source. A source check is not independent confirmation of the source’s claims.","maintainedGuideLinks":[],"conditions":[],"readerContext":{"version":"reader-context-v1","attribution":"Reference context selected by Escape Meridian; separate from source evidence. Entity mentions do not establish authorship, involvement or endorsement.","terms":[],"entities":[]},"researchQuestions":[],"withdrawn":false,"references":{"schemaVersion":1,"target":{"type":"reading","id":"c89b263685637bcfa13d13fc7fcec2fa9ea467ba742faff28cf118368f98591c","revision":"42fc52ab-29af-fbcf-fc11-3a77d7c14ecc","revisionKind":"publication-id","title":"MIT Technology Review reports on Insilico’s AI-designed drug candidate","url":"https://escapemeridian.com/readings/mit-technology-review-reports-on-insilico-s-ai-designed-drug-c89b2636"},"source":{"type":"source","id":"https://www.technologyreview.com/2024/03/20/1089939/a-wave-of-drugs-dreamed-up-by-ai-is-on-its-way/","revision":"d3fee5c2bda2b8df2b91fbe2abaf5e7e65eeb499231265b768f051d2a3006888","revisionKind":"sha256-source-text","title":"An AI-driven “factory of drugs” claims to have hit a big milestone","url":"https://www.technologyreview.com/2024/03/20/1089939/a-wave-of-drugs-dreamed-up-by-ai-is-on-its-way/"},"status":"available","items":[],"next":null,"scope":"Explicit citations in public readings to this reading. Shared topics are not citations. Other record types need an explicit reference adapter."},"revisions":[{"id":"c89b263685637bcfa13d13fc7fcec2fa9ea467ba742faff28cf118368f98591c","title":"MIT Technology Review reports on Insilico’s AI-designed drug candidate","argument":"MIT Technology Review’s article, published March 20, 2024, examines Insilico Medicine’s candidate drug for idiopathic pulmonary fibrosis and the claim that AI helped select both its biological target and chemical structure. Alex Zhavoronkov, Insilico’s co-CEO, says the candidate’s progress through animal testing in 18 months demonstrates that AI can speed drug discovery. The article also describes the candidate’s progress to Phase II trials, which seek initial evidence of whether it helps patients; it does not report that the drug works.\n\nThe article places that claim against a broader uncertainty: many AI-designed drug candidates are advancing, but the cited BCG analysis could not determine whether they progress faster than conventional drugs, and no AI drugs had completed the journey to approval. It also notes that important failures can occur in later patient tests. Zhavoronkov says the drug may still fail and compares its later development to moving at “the speed of traffic.” The article’s central stake is whether the candidate can help people with a fatal lung disease—not whether AI alone can make that happen. Whether this drug helps patients remains unknown.","topicIds":["investment-booms-and-busts"],"domain":"other","claimType":"attributed reading","limits":"Text as retrieved on October 28, 2026; originally published March 20, 2024.","speaker":{"name":"MIT Technology Review","roleAtSource":"Publisher"},"source":{"title":"An AI-driven “factory of drugs” claims to have hit a big milestone","publisher":"MIT Technology Review","format":"Article","url":"https://www.technologyreview.com/2024/03/20/1089939/a-wave-of-drugs-dreamed-up-by-ai-is-on-its-way/","publishedAt":"2024-03-20T10:30:00Z","dateBasis":"Date from the publisher’s own records, through its API."},"evidence":[{"text":"Zhavoronkov says AI helped Insilico choose both the drug’s target and chemical structure.","excerpt":"AI software not only helped decide what target inside a cell to interact with, but also what the drug’s chemical structure should be.","url":"https://www.technologyreview.com/2024/03/20/1089939/a-wave-of-drugs-dreamed-up-by-ai-is-on-its-way/","relationship":"Source-stated"},{"text":"Zhavoronkov says the candidate’s rapid progress through animal testing demonstrates that AI can make drug discovery faster.","excerpt":"it took 18 months for the compound to be synthesized and complete testing in animals—is a demonstration that AI can make drug discovery faster.","url":"https://www.technologyreview.com/2024/03/20/1089939/a-wave-of-drugs-dreamed-up-by-ai-is-on-its-way/","relationship":"Source-stated"},{"text":"The article says the candidate advanced to Phase II trials, which will seek initial evidence of whether it helps patients.","excerpt":"The drug has since advanced to Phase II trials in China and the U.S., which will seek initial evidence of whether it’s actually helpful to patients","url":"https://www.technologyreview.com/2024/03/20/1089939/a-wave-of-drugs-dreamed-up-by-ai-is-on-its-way/","relationship":"Source-stated"},{"text":"The article says the cited BCG analysis could not determine whether AI-enabled drugs were progressing faster than the conventional pace, and that no AI drugs had completed the journey to approval.","excerpt":"What BCG couldn’t determine was if AI-enabled drugs were progressing more quickly than the conventional pace","url":"https://www.technologyreview.com/2024/03/20/1089939/a-wave-of-drugs-dreamed-up-by-ai-is-on-its-way/","relationship":"Source-stated"},{"text":"Zhavoronkov says the candidate can still fail and that later development will move at the speed of traffic.","excerpt":"“It’s like a Tesla. The initial 0 to 60 is very fast, but after that you are moving at the speed of traffic,” he says. “And you can still fail.”","url":"https://www.technologyreview.com/2024/03/20/1089939/a-wave-of-drugs-dreamed-up-by-ai-is-on-its-way/","relationship":"Source-stated"}],"sourceMedia":{"status":"unchecked","sourceUrl":"https://www.technologyreview.com/2024/03/20/1089939/a-wave-of-drugs-dreamed-up-by-ai-is-on-its-way/","checkedAt":null,"items":[]},"assumptions":[],"openQuestion":{"attribution":"Open question","text":"What evidence will the Phase II trials provide about whether Insilico’s candidate helps patients with idiopathic pulmonary fibrosis?"},"whatWouldChangeView":{"attribution":"Change condition not recorded","text":""},"editorialComparisons":[],"live":{"title":"MIT Technology Review reports on Insilico’s AI-designed drug candidate","summary":"MIT Technology Review’s article, published March 20, 2024, examines Insilico Medicine’s candidate drug for idiopathic pulmonary fibrosis and the claim that AI helped select both its biological target and chemical structure. Alex Zhavoronkov, Insilico’s co-CEO, says the candidate’s progress through animal testing in 18 months demonstrates that AI can speed drug discovery. The article also describes the candidate’s progress to Phase II trials, which seek initial evidence of whether it helps patients; it does not report that the drug works.\n\nThe article places that claim against a broader uncertainty: many AI-designed drug candidates are advancing, but the cited BCG analysis could not determine whether they progress faster than conventional drugs, and no AI drugs had completed the journey to approval. It also notes that important failures can occur in later patient tests. Zhavoronkov says the drug may still fail and compares its later development to moving at “the speed of traffic.” The article’s central stake is whether the candidate can help people with a fatal lung disease—not whether AI alone can make that happen. Whether this drug helps patients remains unknown.","question":"What evidence will the Phase II trials provide about whether Insilico’s candidate helps patients with idiopathic pulmonary fibrosis?","claims":[{"text":"Zhavoronkov says AI helped Insilico choose both the drug’s target and chemical structure.","excerpt":"AI software not only helped decide what target inside a cell to interact with, but also what the drug’s chemical structure should be.","support":"source-stated"},{"text":"Zhavoronkov says the candidate’s rapid progress through animal testing demonstrates that AI can make drug discovery faster.","excerpt":"it took 18 months for the compound to be synthesized and complete testing in animals—is a demonstration that AI can make drug discovery faster.","support":"source-stated"},{"text":"The article says the candidate advanced to Phase II trials, which will seek initial evidence of whether it helps patients.","excerpt":"The drug has since advanced to Phase II trials in China and the U.S., which will seek initial evidence of whether it’s actually helpful to patients","support":"source-stated"},{"text":"The article says the cited BCG analysis could not determine whether AI-enabled drugs were progressing faster than the conventional pace, and that no AI drugs had completed the journey to approval.","excerpt":"What BCG couldn’t determine was if AI-enabled drugs were progressing more quickly than the conventional pace","support":"source-stated"},{"text":"Zhavoronkov says the candidate can still fail and that later development will move at the speed of traffic.","excerpt":"“It’s like a Tesla. The initial 0 to 60 is very fast, but after that you are moving at the speed of traffic,” he says. “And you can still fail.”","support":"source-stated"}],"limitations":["Text as retrieved on October 28, 2026; originally published March 20, 2024."],"mediaId":null,"correctionReason":null,"id":"c89b263685637bcfa13d13fc7fcec2fa9ea467ba742faff28cf118368f98591c","publicationId":"42fc52ab-29af-fbcf-fc11-3a77d7c14ecc","version":1,"sourceUrl":"https://www.technologyreview.com/2024/03/20/1089939/a-wave-of-drugs-dreamed-up-by-ai-is-on-its-way/","sourceTitle":"An AI-driven “factory of drugs” claims to have hit a big milestone","publisher":"MIT Technology Review","publishedAt":"2024-03-20T10:30:00Z","originalPublished":{"value":"2024-03-20T10:30:00Z","precision":"instant","basis":"backfill:api_published"},"firstObservedAt":"2026-10-28T15:02:06.919Z","createdAt":"2026-11-20T20:23:09.539Z","historical":true,"entityIds":[],"topicIds":["investment-booms-and-busts"],"media":[],"sourceMedia":{"status":"unchecked","sourceUrl":"https://www.technologyreview.com/2024/03/20/1089939/a-wave-of-drugs-dreamed-up-by-ai-is-on-its-way/","checkedAt":null,"items":[]},"editorialDecision":{"outcome":"accept","mediaId":null,"inputHash":"4c7c7daa022808c3915e1f92727037ed8da5ab10bfbe619a9c992a6aa0fac3c1","rubricVersion":"unrecorded","provider":"typesafe","model":"jev-1.13.0","reasonCodes":["bridge_admitted_by_model"],"confidence":0.73,"decidedAt":"2026-10-28T15:02:04.896Z"},"provenance":{"textHash":"d3fee5c2bda2b8df2b91fbe2abaf5e7e65eeb499231265b768f051d2a3006888","observationId":"23c1c4bc09635a1f34db6362f412fc87a7639ebe0cb56fe00b70e2573637ddc7","retrievedAt":"2026-10-28T15:03:52.567Z","kind":"publisher-page","preparer":{"model":"openai/gpt-6-luna","runId":"15435351-02b8-3cfc-96ca-45f88c173c3e"},"reviewer":{"model":"anthropic/claude-opus-5.5","runId":"e1e21f2a-c6d3-d063-7ef1-c4a9b61207eb"}},"audit":{"status":"uncertain","reviewedAt":"2026-11-20T20:18:41.313Z","model":"anthropic/claude-opus-5.5"}}}],"audits":[{"publicationId":"42fc52ab-29af-fbcf-fc11-3a77d7c14ecc","verdict":"uncertain","findings":[{"dimension":"attribution","status":"pass","explanation":"The reading is correctly attributed to MIT Technology Review. It keeps Zhavoronkov's claims as his and the BCG findings as BCG's. The page is a single reported article, not a listing.","excerpt":"Now he says his company, Insilico Medicine, has created the first “true AI drug”"},{"dimension":"summary","status":"uncertain","explanation":"The reading leaves out a central contested point: Zhavoronkov's claim that this is the first true AI drug. The article says the claim is impossible to affirm, and Recursion's CEO disputes it. Smallest repair: add one sentence noting the 'first' claim and the pushback. The line 'The article's central stake is whether the candidate can help people...not whether AI alone can make that happen' is unlabeled EM framing that the article does not state. It should be removed or labeled as interpretation. The later-failure point comes from 'Some AI skeptics', not the article's own voice. Otherwise the terms are clear to a general reader.","excerpt":"the nebulous definition of AI makes his claim impossible to affirm"},{"dimension":"date","status":"pass","explanation":"March 20, 2024 matches the UTC day of originalPublished. The 2026 retrieval is disclosed and the evidence kind is publisher-page. There is no hindsight framing, and Phase II is reported as ongoing. The 'This summer' CNBC passage and the Deep Dive sidebar may be later or inconsistent additions, but the reading does not rely on them.","excerpt":null},{"dimension":"support","status":"pass","explanation":"Each claim's excerpt appears verbatim in the source and supports its claim, with correct attribution to Zhavoronkov or the article. The question about the Phase II evidence follows from the source and does not presume an outcome.","excerpt":"So far, there’s not enough data to say, since no AI drugs have completed the journey to approval."},{"dimension":"media","status":"pass","explanation":"No media is selected and no verified media candidates were supplied.","excerpt":null}],"createdAt":"2026-11-20T20:18:41.313Z","model":"anthropic/claude-opus-5.5"}],"correctionUrl":"https://escapemeridian.com/corrections/"}